Group Leader/s
Head of lab
intro
Our research group seeks to delve into the cellular and molecular bases of pulmonary vascular dysfunction, the gateway to the body for a multitude of agents capable of compromising people's health. Our research places a special focus on understanding endothelial damage and its connection with vascular smooth muscle and the immune system, all of which are very present in the development of cardiovascular diseases. We go from rare or infrequent diseases such as pulmonary arterial hypertension to other cardiopulmonary disorders resulting from exposure to various environmental factors, such as hypoxia, certain pollutants, drugs or respiratory infections. All these cardiopulmonary diseases affect both the lung vasculature and the heart in one way or another. The ultimate goal of our research is to find new targets, biomarkers and therapeutic strategies that contribute, from basic biology and experimental pharmacology, to solving the health challenges of our society.
Members
| Eduardo Oliver Perez |
| Yolanda Sierra Palomares |
| Daniel Angel Lobato Alonso |
| Noelia Gonzalez Guijarro |
| Andrea Nicole Reyes Flores |
| Bertha Garcia Leon |
Selected Publications
Pun-García, A., Clemente-Moragón, A., Villena-Gutierrez, R., Gómez, M., Sanz-Rosa, D., Díaz-Guerra, A., Prados, B., Medina, J. P., Montó, F., Ivorra, M. D., Márquez-López, C., Cannavo, A., Bernal, J. A., Koch, W. J., Fuster, V., de la Pompa, J. L., Oliver, E., & Ibanez, B. [2022]. Beta-3 adrenergic receptor overexpression reverses aortic stenosis–induced heart failure and restores balanced mitochondrial dynamics. Basic research in cardiology, 117(1), 62.
*Clemente-Moragón, A., *Oliver, E., Calle, D., Cussó, L., Tech, M. G., Pradillo, J. M., Castejón, R., Rallón, N., Benito, J. M., Fernández-Ferro, J. C., Carneado-Ruíz, J., Moro, M. A., Sánchez-González, J., Fuster, V., Cortés-Canteli, M., Desco, M., & Ibáñez, B. (*equally contributed) [2023]. Neutrophil β1 adrenergic receptor blockade blunts stroke-associated neuroinflammation. British journal of pharmacology, 180:459–478
*Clemente-Moragón, A., *Martínez-Milla, J., Oliver, E., Santos, A., Flandes, J., Fernández, I., Rodríguez-González, L., Serrano Del Castillo, C., Ioan, A. M., López-Álvarez, M., Gómez-Talavera, S., Galán-Arriola, C., Fuster, V., Pérez-Calvo, C., & Ibáñez, B. (*equally contributed) [2021]. Metoprolol in Critically Ill Patients With COVID-19. Journal of the American College of Cardiology, 78(10), 1001–1011.
Galán-Arriola, C., Vílchez-Tschischke, J. P., Lobo, M., López, G. J., de Molina-Iracheta, A., Pérez-Martínez, C., Villena-Gutiérrez, R., Macías, Á., Díaz-Rengifo, I. A., Oliver, E., Fuster, V., Sánchez-González, J., & Ibanez, B. [2022]. Coronary microcirculation damage in anthracycline cardiotoxicity. Cardiovascular research, 118(2), 531–541.
Galán-Arriola, C., Villena-Gutiérrez, R., Higuero-Verdejo, M. I., Díaz-Rengifo, I. A., Pizarro, G., López, G. J., Molina-Iracheta, A., Pérez-Martínez, C., García, R. D., González-Calle, D., Lobo, M., Sánchez, P. L., Oliver, E., Córdoba, R., Fuster, V., Sánchez-González, J., & Ibanez, B. [2021]. Remote ischaemic preconditioning ameliorates anthracycline-induced cardiotoxicity and preserves mitochondrial integrity. Cardiovascular research, 117(4), 1132–1143.
Clemente-Moragón, A., Gómez, M., Villena-Gutiérrez, R., Lalama, D. V., García-Prieto, J., Martínez, F., Sánchez-Cabo, F., Fuster, V., *Oliver, E., & *Ibáñez, B. (*co-corresponding authors) [2020]. Metoprolol exerts a non-class effect against ischaemia-reperfusion injury by abrogating exacerbated inflammation. European heart journal, 41(46), 4425–4440.
Spaczyńska, M., Rocha, S. F., & *Oliver, E. (*corresponding author) [2020]. Pharmacology of Pulmonary Arterial Hypertension: An Overview of Current and Emerging Therapies. ACS pharmacology & translational science, 3(4), 598–612.
Nuche, J., Segura de la Cal, T., Jiménez López Guarch, C., López-Medrano, F., Delgado, C. P., Ynsaurriaga, F. A., Delgado, J. F., Ibáñez, B., *Oliver, E., & *Subías, P. E. (*co-corresponding authors). [2020]. Effect of Coronavirus Disease 2019 in Pulmonary Circulation. The Particular Scenario of Precapillary Pulmonary Hypertension. Diagnostics (Basel, Switzerland), 10(8), 548.
*Oliver, E., Mayor, F., Jr, & D'Ocon, P. (*corresponding author). [2019]. Beta-blockers: Historical Perspective and Mechanisms of Action. Revista espanola de cardiologia (English ed.), 72(10), 853–862.
*Zhao, L., *Oliver, E., Maratou, K., Atanur, S. S., Dubois, O. D., Cotroneo, E., Chen, C. N., Wang, L., Arce, C., Chabosseau, P. L., Ponsa-Cobas, J., Frid, M. G., Moyon, B., Webster, Z., Aldashev, A., Ferrer, J., Rutter, G. A., Stenmark, K. R., Aitman, T. J., & Wilkins, M. R. (*co-first authors). [2015]. The zinc transporter ZIP12 regulates the pulmonary vascular response to chronic hypoxia. Nature, 524(7565), 356–360.
Funding
Funded by Ministerio de Ciencia e Innovación / Agencia Estatal de Investigación (RYC2020-028884-I and PID2021-123167OB-I00); by CSIC Talent Attraction program (PIE 20222AT010) and by Programa de Investigo program from Comunidad de Madrid and European Union - Next Generation EU (09-PIN1-00004.3/2022 – (19)Sanidad-CIB(2))
 |
 |
|
|
More info
Patents
Oliver E, Zhao L, Wilkins MR, and Aitman T. PCT/GB2016/052297. ZIP12 as a Therapeutic/Screening Candidate for Hypoxia-Induced Pulmonary Hypertension WO/2017/017446. Priority: UK (extended to world-wide application), Date: 28/07/2015. Status: entered into national phases in EP and US. Holder: Imperial Innovations Ltd.
Honors and Awards
- Ramón y Cajal Fellow. Agencia Estatal de Investigación. 2022-2017
- ‘Prismas’ Honorific mention to the singular project modality for the initiative #CienciaenelParlamento. Museos Científicos Coruñeses. 2019
- SRUK Mentoring recognition award. SRUK/CERU. 2018
- Talent Atraction Senior Fellow (mod.1). Comunidad Autónoma de Madrid. 2018-2022
- 1st Prize in Biological and Biomedical Sciences for Tutors. 16th ARQUIMEDES University Contest. Ministry of Education, Culture and Sports. 2017
- Winner of the 32nd SEF Young Investigator Award to best career under 35 years old. Spanish Society of Pharmacology (SEF). 2017
- Winner of the EPHAR Young Investigator Award. The Federation of European Pharmacological Societies (EPHAR). 2016
- International Postdoctoral CNIC Fellow. Marie Sklodowska-Curie COFUND. 2016-2018
- Expert on expatriate scientific networks. 'Los 100 de Cotec', Fundacion Cotec. 2016
- FPU Phd Fellow. Ministry of Science and Education. 2005-2009
RECENT NEWS about the group, click here.
*We are looking for candidates to do a Master and/or PhD with us! If you are interested in joining our group, send an e-mail to Eduardo including your CV and a motivation letter.
We are part of:
|
|
|
|
